Literature DB >> 18313813

Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction.

Victòria E Sevil Domènech1, Klaus Panthel, Sebastian E Winter, Holger Rüssmann.   

Abstract

Pre-existing anti-vector immunity can severely compromise the ability of Salmonella enterica serovar Typhimurium live vaccines to induce protective CD8 T-cell frequencies after type III secretion system-mediated heterologous protein translocation in orally immunized mice. In the present study, we demonstrate that heterologous prime-boost immunizations using attenuated serovar Typhimurium and serovar Dublin strains for foreign antigen delivery can be employed to bypass anti-Salmonella immunity resulting in enhanced antigen-specific CD8 T-cell induction. This desirable effect can be explained by the fact that, in contrast to homologous prime-boost immunizations, vaccination with different Salmonella serovars is characterized by long-lasting colonization of mice by both live carrier vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313813     DOI: 10.1016/j.vaccine.2008.01.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.

Authors:  Chee-Mun Fang; Jin Yuan Wang; Magaly Chinchilla; Myron M Levine; William C Blackwelder; James E Galen
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

2.  A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

Authors:  Audrey Le Gouëllec; Xavier Chauchet; David Laurin; Caroline Aspord; Julien Verove; Yan Wang; Charlotte Genestet; Candice Trocme; Mitra Ahmadi; Sandrine Martin; Alexis Broisat; François Cretin; Catherine Ghezzi; Benoit Polack; Joël Plumas; Bertrand Toussaint
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

3.  Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium.

Authors:  Christina Berchtold; Klaus Panthel; Stefan Jellbauer; Brigitte Köhn; Elisabeth Roider; Miriam Partilla; Jürgen Heesemann; Stefan Endres; Carole Bourquin; Holger Rüssmann
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

4.  Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.

Authors:  Manvendra Saxena; Peter J Coloe; Peter M Smooker
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

Review 5.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Authors:  Laurence M Wood; Yvonne Paterson
Journal:  Front Cell Infect Microbiol       Date:  2014-05-12       Impact factor: 5.293

Review 6.  Pre-existing immunity against vaccine vectors--friend or foe?

Authors:  Manvendra Saxena; Thi Thu Hao Van; Fiona J Baird; Peter J Coloe; Peter M Smooker
Journal:  Microbiology       Date:  2012-11-22       Impact factor: 2.777

7.  Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery.

Authors:  Heather A Carleton; María Lara-Tejero; Xiaoyun Liu; Jorge E Galán
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  An oral recombinant Salmonella enterica serovar Typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice.

Authors:  Nyasha Chin'ombe; William R Bourn; Anna-Lise Williamson; Enid G Shephard
Journal:  Gut Pathog       Date:  2009-04-29       Impact factor: 4.181

Review 9.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

10.  Recombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines.

Authors:  Nyasha Chin'ombe; Vurayai Ruhanya
Journal:  Open Virol J       Date:  2013-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.